// App-Quantinova.ai

e15739 : Nab-paclitaxel/gemcitabine first-line therapy in patients with metastatic pancreatic carcinoma and high-bilirubin levels: Data from the German QoliXane Pancreatic Cancer Registry.

Researchers

Presenter

  • Gerrit zur Hausen

Principal Investigators

  • Oliver Waidmann

  • Marcus A. Woerns

  • Heinz-Gert Hoeffkes

  • Steffen Doerfel

  • Mark-Oliver Zahn

  • Ali Aldaoud

  • Martina Stauch

  • Christoph Springfeld

  • Nicolai Haertel

  • Alexander Reichart

  • Claudia Pauligk

  • Josefine Roemmler-Zehrer

  • Ralf Hofheinz

  • Salah-Eddin Al-Batran

Medical Centers

  • Institut of Clinical Cancer Research - University Cancer Center Frankfurt, Frankfurt, Germany

  • University Hospital Frankfurt, Frankfurt, Germany

  • Medical University Clinic, Tuebingen, Germany

  • Klinikum Fulda gAG, Fulda, Germany

  • Onkozentrum Dresden, Dresden, Germany

  • Private Practice, Goslar, Germany

  • Forschungsgemeinschaft Aldaoud/Schwarzer, Leipzig, Germany

  • Onkologische Schwerpunktpraxis Kronach, Kronach, Germany

  • NCT Nationales Centrum fuer Tumorerkrankungen Heidelberg, Heidelberg, Germany

  • University Medical Center Mannheim, Mannheim, Germany

  • Institut of Clinical Cancer Research - University Cancer Center Frankfurt, Frankfurt, Germany

  • Amgen GmbH, Munich, Germany

  • University Hospital Mannheim, Mannheim, Germany

Locations

  • Germany

Companies

  • Celgene GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic pancreatic adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • Bilirubin

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved